Two-in-one protein tag enables the soluble expression and calcium-dependent purification of single-chain antibody fragments

1. Wang, Y. et al. A 33-residue peptide tag increases solubility and stability of Escherichia coli produced single-chain antibody fragments. Nat. Commun. 13, 4614 (2022).

   Google Scholar 

2. Ryman, J. T. & Meibohm, B. Pharmacokinetics of monoclonal antibodies. CPT Pharmacomet. Syst. Pharmacol. 6, 576–588 (2017).

   Google Scholar 

3. Weiner, L. M., Surana, R. & Wang, S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat. Rev. Immunol. 10, 317–327 (2010).

   Google Scholar 

4. Samaranayake, H., Wirth, T., Schenkwein, D., Räty, J. K. & Ylä-Herttuala, S. Challenges in monoclonal antibody-based therapies. Ann. Med. 41, 322–331 (2009).

   Google Scholar 

5. Wang-Lin, S. X. & Balthasar, J. P. Pharmacokinetic and pharmacodynamic considerations for the use of monoclonal antibodies in the treatment of bacterial infections. Antibodies 7, 5 (2018).

   Google Scholar 

6. Li Z. et al Influence of molecular size on tissue distribution of antibody fragments. In:MAbs). (Taylor & Francis, 2016).

7. Hussain, K. et al. Impact of human FcγR gene polymorphisms on IgG-triggered cytokine release: critical importance of cell assay format. Front. Immunol. 10, 390 (2019).

   Google Scholar 

8. Rodríguez-Nava, C. et al. Mechanisms of action and limitations of monoclonal antibodies and single chain fragment variable (scFv) in the treatment of cancer. Biomedicines 11, 1610 (2023).

   Google Scholar 

9. Liu, R., Oldham, R. J., Teal, E., Beers, S. A. & Cragg, M. S. Fc-engineering for modulated effector functions—improving antibodies for cancer treatment. Antibodies 9, 64 (2020).

   Google Scholar 

10. Duranti, C. et al. Generation and characterization of novel recombinant anti-hERG1 scFv antibodies for cancer molecular imaging. Oncotarget 9, 34972 (2018).

    Google Scholar 

11. Muñoz-López, P. et al. Single-chain fragment variable: recent progress in cancer diagnosis and therapy. Cancers 14, 4206 (2022).

    Google Scholar 

12. Weisser, N. E. & Hall, J. C. Applications of single-chain variable fragment antibodies in therapeutics and diagnostics. Biotechnol. Adv. 27, 502–520 (2009).

    Google Scholar 

13. Pirkalkhoran, S. et al. Bioengineering of antibody fragments: challenges and opportunities. Bioengineering 10, 122 (2023).

    Google Scholar 

14. Shin, C., Kim, S. S. & Jo, Y. H. Extending traditional antibody therapies: Novel discoveries in immunotherapy and clinical applications. Mol. Ther.-Oncol. 22, 166–179 (2021).

    Google Scholar 

15. Sun, W. et al. A combined strategy improves the solubility of aggregation-prone single-chain variable fragment antibodies. Protein Expr. Purif. 83, 21–29 (2012).

    Google Scholar 

16. Ahmadzadeh, M., Farshdari, F., Nematollahi, L., Behdani, M. & Mohit, E. Anti-HER2 scFv expression in Escherichia coli SHuffle® T7 express cells: effects on solubility and biological activity. Mol. Biotechnol. 62, 18–30 (2020).

    Google Scholar 

17. Montoliu-Gaya, L., Martínez, J. C. & Villegas, S. Understanding the contribution of disulfide bridges to the folding and misfolding of an anti-Aβ scFv. Protein Sci. 26, 1138–1149 (2017).

    Google Scholar 

18. Glockshuber, R., Schmidt, T. & Plueckthun, A. The disulfide bonds in antibody variable domains: effects on stability, folding in vitro, and functional expression in Escherichia coli. Biochemistry 31, 1270–1279 (1992).

    Google Scholar 

19. Scheffel, J., Larsson, E., Öst, L. & Hober, S. Calcium-dependent affinity ligands for the purification of antibody fragments at neutral pH. J. Chromatogr. A 1694, 463902 (2023).

    Google Scholar 

20. Rodrigo, G., Gruvegård, M. & Van Alstine, J. M. Antibody fragments and their purification by protein L affinity chromatography. Antibodies 4, 259–277 (2015).

    Google Scholar 

21. Sarker, A., Rathore, A. S. & Gupta, R. D. Evaluation of scFv protein recovery from E. coli by in vitro refolding and mild solubilization process. Microb. Cell Factories 18, 1–12 (2019).

    Google Scholar 

22. Fursova, K. et al. Refolding of scFv mini-antibodies using size-exclusion chromatography via arginine solution layer. J. Chromatogr. B 877, 2045–2051 (2009).

    Google Scholar 

23. Ferré, H. et al. A novel system for continuous protein refolding and on-line capture by expanded bed adsorption. Protein Sci. 14, 2141–2153 (2005).

    Google Scholar 

24. Yang, J., Moyana, T., MacKenzie, S., Xia, Q. & Xiang, J. One hundred seventy-fold increase in excretion of an FV fragment-tumor necrosis factor alpha fusion protein (sFV/TNF-α) from Escherichia coli caused by the synergistic effects of glycine and Triton X-100. Appl. Environ. Microbiol. 64, 2869–2874 (1998).

    Google Scholar 

25. Maeng, B. H., Nam, D. H. & Kim, Y. H. Coexpression of molecular chaperones to enhance functional expression of anti-BNP scFv in the cytoplasm of Escherichia coli for the detection of B-type natriuretic peptide. World J. Microbiol. Biotechnol. 27, 1391–1398 (2011).

    Google Scholar 

26. Thie, H., Schirrmann, T., Paschke, M., Dübel, S. & Hust, M. SRP and Sec pathway leader peptides for antibody phage display and antibody fragment production in E. coli. N. Biotechnol. 25, 49–54 (2008).

    Google Scholar 

27. Jurado, P., de Lorenzo, V. & Fernández, L. A. Thioredoxin fusions increase folding of single chain Fv antibodies in the cytoplasm of Escherichia coli: evidence that chaperone activity is the prime effect of thioredoxin. J. Mol. Biol. 357, 49–61 (2006).

    Google Scholar 

28. Ye, T., Lin, Z. & Lei, H. High-level expression and characterization of an anti-VEGF165 single-chain variable fragment (scFv) by small ubiquitin-related modifier fusion in Escherichia coli. Appl. Microbiol. Biotechnol. 81, 311–317 (2008).

    Google Scholar 

29. Hayhurst, A. Improved expression characteristics of single-chain Fv fragments when fused downstream of the Escherichia coli maltose-binding protein or upstream of a single immunoglobulin-constant domain. Protein Expr. Purif. 18, 1–10 (2000).

    Google Scholar 

30. Kowalik, A. et al. Dopamine D2 and Serotonin 5-HT1A dimeric receptor-binding monomeric antibody scFv as a potential ligand for carrying drugs targeting selected areas of the brain. Biomolecules 12, 749 (2022).

    Google Scholar 

31. Łukasiewicz S. et al. Different strategies used in the production of human monoclonal scfv antibodies specific to dimers of membrane receptors. J. Biol. Med. 3, 7 (2019).

32. Petrus, M. L. et al. A microbial expression system for high-level production of scFv HIV-neutralizing antibody fragments in Escherichia coli. Appl. Microbiol. Biotechnol. 103, 8875–8888 (2019).

    Google Scholar 

33. Wang, Q. & Michalak, M. Calsequestrin. Structure, function, and evolution. Cell Calcium 90, 102242 (2020).

    Google Scholar 

34. Marabelli, C., Santiago, D. J. & Priori, S. G. The structural–functional crosstalk of the calsequestrin system: insights and pathological implications. Biomolecules 13, 1693 (2023).

    Google Scholar 

35. Sibbles E. T., Waddell H. M., Mereacre V., Jones P. P., Munro M. L. The function and regulation of calsequestrin-2: Implications in calcium-mediated arrhythmias. Biophys. Rev. 7, 329–352 (2022).

36. Nguyen, Q. D. et al. Brolucizumab: evolution through preclinical and clinical studies and the implications for the management of neovascular age-related macular degeneration. Ophthalmology 127, 963–976 (2020).

    Google Scholar 

37. Goebeler, M.-E. & Bargou, R. Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy. Leuk. lymphoma 57, 1021–1032 (2016).

    Google Scholar 

38. Zhang, H. et al. Therapeutic potential of an anti-HER2 single chain antibody–DM1 conjugates for the treatment of HER2-positive cancer. Signal Transduct. Target. Ther. 2, 1–11 (2017).

    Google Scholar 

39. De Marco, A. Strategies for successful recombinant expression of disulfide bond-dependent proteins in Escherichia coli. Microb. Cell Factories 8, 1–18 (2009).

    Google Scholar 

40. Nguyen, M. T. et al. Prokaryotic soluble overexpression and purification of human VEGF165 by fusion to a maltose binding protein tag. PloS ONE 11, e0156296 (2016).

    Google Scholar 

41. Su, Y., Zou, Z., Feng, S., Zhou, P. & Cao, L. The acidity of protein fusion partners predominantly determines the efficacy to improve the solubility of the target proteins expressed in Escherichia coli. J. Biotechnol. 129, 373–382 (2007).

    Google Scholar 

42. Fox, J. D., Kapust, R. B. & Waugh, D. S. Single amino acid substitutions on the surface of Escherichia coli maltose-binding protein can have a profound impact on the solubility of fusion proteins. Protein Sci. 10, 622–630 (2001).

    Google Scholar 

43. Zhang, Y.-B. et al. Protein aggregation during overexpression limited by peptide extensions with large net negative charge. Protein Expr. Purif. 36, 207–216 (2004).

    Google Scholar 

44. Grana-Montes, R., Marinelli, P., Reverter, D. & Ventura, S. N-Terminal protein tails act as aggregation protective entropic bristles: the SUMO case. Biomacromolecules 15, 1194–1203 (2014).

45. Tang, N. C. et al. Synthetic intrinsically disordered protein fusion tags that enhance protein solubility. Nat. Commun. 15, 3727 (2024).

    Google Scholar 

46. Abeln, S. & Frenkel, D. Disordered flanks prevent peptide aggregation. PLoS Comput. Biol. 4, e1000241 (2008).

    Google Scholar 

47. Santner, A. A. et al. Sweeping away protein aggregation with entropic bristles: intrinsically disordered protein fusions enhance soluble expression. Biochemistry 51, 7250–7262 (2012).

    Google Scholar 

48. Sanchez, E. J., Lewis, K. M., Danna, B. R. & Kang, C. High-capacity Ca2+ binding of human skeletal calsequestrin. J. Biol. Chem. 287, 11592–11601 (2012).

    Google Scholar 

49. Cozens, B. & Reithmeier, R. Size and shape of rabbit skeletal muscle calsequestrin. J. Biol. Chem. 259, 6248–6252 (1984).

    Google Scholar 

50. Micsonai, A. et al. Disordered–ordered protein binary classification by circular dichroism spectroscopy. Front. Mol. Biosci. 9, 863141 (2022).

    Google Scholar 

51. Adler A. J., Greenfield N. J., Fasman G. D. [27] Circular dichroism and optical rotatory dispersion of proteins and polypeptides. In: Methods in Enzymology). (Elsevier, 1973).

52. Hu, X. et al. High-yield biosynthesis process and characterization of brolucizumab. Pharm. Fronts 7, e233–e244 (2025).

    Google Scholar 

53. Kim, H. M. & Woo, S. J. Immunogenicity and potential for intraocular inflammation of intravitreal anti-VEGF drugs. Curr. Therapeutic Res. 100, 100742 (2024).

    Google Scholar 

54. Bowley, S. R., Fang, C., Merrill-Skoloff, G., Furie, B. C. & Furie, B. Protein disulfide isomerase secretion following vascular injury initiates a regulatory pathway for thrombus formation. Nat. Commun. 8, 14151 (2017).

    Google Scholar 

55. Yu, S. et al. A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells. J. Exp. Clin. Cancer Res. 38, 355 (2019).

    Google Scholar 

56. Rosano, G. L. & Ceccarelli, E. A. Recombinant protein expression in Escherichia coli: advances and challenges. Front. Microbiol. 5, 172 (2014).

    Google Scholar 

57. Nguyen, T. K. O. et al. Soluble prokaryotic overexpression and purification of human GM-CSF using the protein disulfide isomerase b′ a′ domain. Int. J. Mol. Sci. 22, 5267 (2021).

    Google Scholar 

58. Byun, K. T. et al. Development of an anti-HER2 single-chain variable antibody fragment construct for high-yield soluble expression in escherichia coli and one-step chromatographic purification. Biomolecules 13, 1508 (2023).

    Google Scholar 

59. Boucher L. E. et al. “Stapling” scFv for multispecific biotherapeutics of superior properties. In: Mabs). (Taylor & Francis, 2023).

60. Akbarian, M. & Chen, S.-H. Instability challenges and stabilization strategies of pharmaceutical proteins. Pharmaceutics 14, 2533 (2022).

    Google Scholar 

Download references